ICU Medical, Inc. ICUI
164.95
(1.07)
(0.64%)
as of 25 Sep
- Market cap
- $4.2B
- P/E
- 137×
Follow ICUI
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
122.17 | 69.06 | 7,133.50 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.70 | 1.48 | 1.58 | 1.28 | |
P/FCF ratio |
23.97 | 38.97 | 38.68 | 47.51 | |
P/Operating CF |
45.73 | 82.20 | 58.01 | 52.22 | |
P/B ratio |
1.70 | 1.51 | 1.66 | 1.39 | |
Price to Tangible BV |
36.72 | 116.73 | 0.00 | 0.00 | |
EV/Sales |
2.13 | 1.94 | 2.01 | 1.73 | |
EV/EBITDA |
16.56 | 16.76 | 17.99 | 14.14 | |
EV/Operating CF |
19.45 | 25.03 | 24.98 | 25.23 | |
EV/FCF |
30.07 | 51.06 | 49.42 | 64.55 | |
Quick Ratio |
0.97 | 0.95 | 0.98 | 1.00 | |
Current Ratio |
2.43 | 2.34 | 2.39 | 2.45 | |
Net Debt/EBITDA |
10.42 | 15.41 | 16.98 | 15.33 | |
Debt/Assets |
31.00% | 31.90% | 31.72% | 32.02% | |
Debt/Equity |
0.57 | 0.61 | 0.60 | 0.62 | |
Asset Turnover |
0.53 | 0.53 | 0.54 | 0.55 | |
Operating CF/Net income |
4.20 | 1.29 | (3.85) | (16.70) | |
Capex/Depreciation |
(0.40) | (0.26) | (0.35) | (0.61) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
4.12% | 4.01% | 3.90% | 3.96% | |
Selling, General and Administrative Expense of Revenue |
27.54% | 29.15% | 28.82% | 28.45% | |
Intangible Assets out of Total Assets |
0.52 | 0.52 | 0.53 | 0.53 | |
Share Based Compensation of Revenue |
2.15% | 2.64% | 2.57% | 2.84% | |
Graham Net Nets |
(0.17) | (0.22) | (0.21) | (0.26) | |
Graham Number |
48.21 | 59.90 | 6.23 | 0.00 | |
Earnings Yield |
0.82% | 1.45% | 0.01% | (0.26%) | |
Free Cash Flow Yield |
4.17% | 2.57% | 2.59% | 2.10% | |
Revenue per Share |
22.07 | 21.41 | 21.94 | 21.75 | |
Operating CF per Share |
3.21 | 1.57 | 2.46 | 2.30 | |
Capex per Share |
(0.81) | (0.53) | (0.75) | (1.29) | |
Free Cash Flow per Share |
2.40 | 1.04 | 1.71 | 1.01 | |
Cash per Share |
11.93 | 11.64 | 12.50 | 12.14 | |
Shareholders Equity per Share |
86.07 | 85.28 | 86.19 | 86.17 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
86.07 | 85.28 | 86.19 | 86.17 | |
Free Cash Flow |
60.01 | 25.70 | 42.21 | 24.96 | |
Working Capital |
712.54 | 695.34 | 691.69 | 714.39 | |
Capital Expenditures |
(20.14) | (13.21) | (18.39) | (31.75) | |
Net Current Asset Value |
(608.52) | (688.59) | (736.13) | (768.36) | |
EV/EBIT |
63.81 | 96.29 | 104.88 | 53.73 | |
Capex to Sales |
0.04 | 0.02 | 0.03 | 0.06 | |
Net Profit Margin |
3.46% | 5.68% | (2.91%) | (0.63%) | |
Price to Operating Income |
50.86 | 73.49 | 82.08 | 39.55 | |
| Other line items | |||||
Average Receivables |
181.51 | 186.00 | 181.67 | 182.76 | |
Average Payables |
158.99 | 177.20 | 151.20 | 170.16 | |
Average Inventory |
611.95 | 597.96 | 600.27 | 657.24 | |
Average Assets |
4,039.34 | 4,099.17 | 4,127.22 | 4,203.97 | |
Average Common Equity |
2,133.81 | 2,049.81 | 2,044.53 | 2,087.92 |
Columns are period end dates